Vaxneuvance's 'immunogenicity' brings competitive edge
By Whang, byung-woo | translator Alice Kang
25.04.02 05:34:06
가나다라
0
One year after Vaxneuvance's addition to the NIP, the drug is expanding its presence in the market based on its immunogenicity.
KDCA approves Prevnar 20 for the NIP… Prevnar 20 became a competitor to Vaxneuvance after its launch.
The initial market share of each vaccine may be determined by the NIP vaccine cross-inoculation schedule.
▲ Soo-Eun Park, Professor of pediatrics at Pusan National University Yangsan
With changes in the market for pneumococcal vaccines ahead, MSD Korea has begun to defend its market share by highlighting the “immunogenicity” of Vaxneuvance.
Last year, the product was launched and added to the National Immunization Program (NIP), accelerating its market penetration. Celebrating its first year in the NIP, the company has been emphasizing Vaxneuvance’s clinical benefits to gain a competitive edge.
On the 1st, MSD Korea held a Vaxneuvance media seminar to highlight the changes and implications of Vaxneuvance’s first year as part of the NIP.
Vaxneuvance, which was approved at the end of 2023, has the characteristics of a 15-valent vaccine, adding seroty
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)